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Enhanced Cellular Adenosine Uptake Limits Adenosine
Receptor Stimulation in Patients
With Hyperhomocysteinemia
Niels P. Riksen, Gerard A. Rongen, Godfried H.J. Boers, Henk J. Blom,
Petra H.H. van den Broek, Paul Smits
Objective—Endogenous adenosine has several cardioprotective effects. We postulate that in patients with hyperhomocys-
teinemia increased intracellular formation of S-adenosylhomocysteine decreases free intracellular adenosine. Subse-
quently, facilitated diffusion of extracellular adenosine into cells through dipyridamole-sensitive transporters is
enhanced, limiting adenosine receptor stimulation. We tested this hypothesis in patients with classical homocystinuria
(n9, plasma homocysteine 93.124.7 mol/L) and matched controls (n8, homocysteine 9.11.0).
Methods and Results—Infusion of adenosine (0.5, 1.5, 5.0, and 15.0 g/min/dL forearm) into the brachial artery increased
forearm blood flow, as measured with venous occlusion plethysmography, to 2.90.4, 4.30.5, 5.61.1, and 9.62.1
in the patients and to 2.80.6, 4.41.0, 9.01.7, and 17.03.1 mL/min/dL in controls (P0.05). However,
adenosine-induced vasodilation in the presence of dipyridamole (100 g/min/dL) was similar in both groups (P0.9).
Additionally, in isolated erythrocytes, adenosine uptake was accelerated by incubation with homocysteine (half-time
6.40.3 versus 8.10.5 minutes, P0.001) associated with increased intracellular formation of
S-adenosylhomocysteine (P0.0001).
Conclusions—In hyperhomocysteinemia, adenosine-induced vasodilation is impaired but is restored by dipyridamole.
Accelerated cellular adenosine uptake probably accounts for these observations. These impaired actions of adenosine
could well contribute to the cardiovascular complications of hyperhomocysteinemia. (Arterioscler Thromb Vasc Biol.
2005;25:109-114.)
Key Words: adenosine  hyperhomocysteinemia  dipyridamole  forearm  nucleoside transport
Hyperhomocysteinemia is an independent risk factor foratherosclerosis and thromboembolism. It is poorly un-
derstood which mechanism is responsible for these cardio-
vascular complications.
Recently, we and others have drawn attention to a new
hypothesis, focusing on the influence of homocysteine on
the metabolism of the endogenous nucleoside adenosine.1,2
According to this hypothesis, a homocysteine-induced fall
in extracellular adenosine contributes to the cardiovascular
sequelae of hyperhomocysteinemia. Fundamental to this is the
reversibility of the reaction in which S-adenosylhomocysteine
(AdoHcy) is hydrolyzed to form homocysteine and adenosine.3
Although the equilibrium constant of this reaction favors
AdoHcy synthesis, under physiological conditions AdoHcy is
hydrolyzed to homocysteine and adenosine, because both reac-
tion products are rapidly metabolized. In hyperhomocysteine-
mia, the reaction shifts toward AdoHcy synthesis at the expense
of free intracellular adenosine. Subsequently, facilitated diffu-
sion of extracellular adenosine into the cells through the dipyr-
idamole-sensitive equilibrative nucleoside transporter is en-
hanced, limiting stimulation of membrane-bound adenosine
receptors (Figure 1).
By stimulation of these receptors, extracellular adeno-
sine induces several effects, which could protect against
the development of atherosclerosis and thrombosis and
against ischemia-reperfusion injury.1,4 Particularly in situ-
ations of hypoxia or ischemia, when the concentration of
adenosine increases rapidly, these effects work in concert
to protect the affected tissue.5 Previous animal studies
suggest that the effect of intracellular AdoHcy formation
on the transmembranous adenosine gradient and thus
diffusion of extracellular adenosine into the cells is most
pronounced in these very situations of high concentrations
of adenosine, thus limiting adenosine receptor stimulation
when most needed.6,7 Therefore, we speculate that in
hyperhomocysteinemia, decreased extracellular adenosine
concentrations contribute to the development of the asso-
ciated cardiovascular problems.
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In the present study, we addressed this issue in patients
with severe hyperhomocysteinemia. We estimated basal in-
travascular and muscle interstitial adenosine concentration by
microdialysis. Secondly, we measured adenosine-induced
forearm vasodilation. According to our hypothesis, acceler-
ated cellular adenosine uptake would decrease the amount of
free extracellular adenosine able to stimulate adenosine re-
ceptors and, consequently, would attenuate adenosine-
induced vasodilation in this patient group. Inhibition of
cellular adenosine uptake by dipyridamole should restore this
diminished response. Additionally, we aimed to more directly
demonstrate homocysteine-induced increased intracellular
formation of AdoHcy and subsequent accelerated adenosine
uptake in isolated human erythrocytes.
Methods
Subjects
After approval of the local ethics committee, adult patients with
hyperhomocysteinemia due to homozygous cystathionine –syn-
thase deficiency from our outpatient clinic were asked to participate
if their fasting total plasma homocysteine was more than 20 mol/L
despite treatment. Exclusion criteria were mental retardation, previ-
ous vascular events, asthma, and oral anticoagulation. Twelve
patients were considered eligible, and nine agreed to participate and
signed informed consent. Their homocysteine-lowering therapy con-
sisted of vitamin B6 (250 to 750 mg, n9), folic acid (5 mg, n9),
vitamin B12 (10 g orally each day or 1 mg intramuscularly each
two months, n7), and betaine anhydricum (6 g, n7). Further
treatment consisted only of acetylsalicylic acid (80 mg in one patient;
stopped one week before the experiment) and alendronic acid (70 mg
weekly in 2 patients). A control group of eight healthy volunteers
was composed with similar age and body mass index as the
patient group.
Instrumentation
All tests were performed in the morning in a temperature-controlled
laboratory (23°C) after an overnight fast and 24 hours of
caffeine abstinence.
After local anesthesia (xylocaine 2%), a microdialysis probe
(CMA/70 microdialysis catheter, Microdialysis AB) was inserted
into the flexor digitorum superficialis muscle of the nondominant
arm, guided by a 14-gauge venflon cannula. An identical microdi-
alysis probe was inserted into a deep antecubital vein of the same
arm. Each probe was connected to a microdialysis pump (CMA/107
microdialysis pump, Microdialysis AB) and continuously perfused
with isotonic saline at 2 L/min. The effluent was collected at
15-minute intervals to obtain 30-L samples (dialysate). Samples
were stored at 20°C until analysis.
Subsequently, the brachial artery of the nondominant arm was
cannulated and forearm blood flow (FBF) was measured in each arm
using mercury-in-silastic venous occlusion plethysmography as de-
scribed previously.8 Each drug dosage was infused for 5 minutes.
In the first hour of the study, blood was drawn for determination
of plasma total homocysteine, AdoHcy, S-adenosylmethionine
(AdoMet), vitamin B6, folate, vitamin B12, and cholesterol.
Experimental Protocol
Immediately after insertion of the microdialysis probes, dialysate
sampling was started. Two hours after insertion, both microdialysis
probes were removed and suspended in isotonic saline for in vitro
calibration, as previously described.9
Subsequently, baseline FBF was measured during infusion of
saline followed by infusion of increasing dosages of adenosine (0.5,
1.5, 5, and 15 g/min/dL forearm). After 30 minutes of equilibration,
baseline FBF measurement was repeated, followed by infusion of
dipyridamole (100 g/min/dL) and increasing dosages of adenosine
(0.15, 0.5, and 1.5 g/min/dL) on top of dipyridamole infusion. In
combination with dipyridamole, we used lower concentrations of
adenosine because of the well-known potentiating effect of dipyri-
damole on adenosine-induced vasodilation.10 Finally, maximal va-
sodilation was measured during postocclusive reactive hyperemia to
test for possible structural vascular changes in the patient group, as
described previously.8
Adenosine Uptake in Isolated Erythrocytes
In 6 additional healthy volunteers, erythrocytes were isolated for in
vitro experiments. In hyperhomocysteinemia, erythrocytes are rele-
vant in the regulation of circulating endogenous adenosine because
adenosine is efficiently taken up by erythrocytes through the dipyridam-
ole-sensitive transporter and because homocysteine and AdoHcy are
increased in erythrocytes of patients with hyperhomocysteinemia.11–13
Freshly isolated erythrocytes were resuspended in MOPS buffer to
obtain a 2% solution. Fifty-L portions were incubated at 37°C with
L-homocysteine (100 mol/L) in DTT and with DTT alone for 10
minutes (paired experiments). Subsequently, adenosine was added in
a final concentration of 1 mol/L. After 0, 3, 6, 10, and 15 minutes,
adenosine uptake and deamination were completely blocked with
high-dose dipyridamole (10 mol/L) and erythro-9-(2-hydroxynon-
3-yl)-adenine (8 mol/L), respectively. Subsequently, after centrif-
ugation through a dibutylphtalate layer, the adenosine concentration
in the supernatant and the AdoHcy concentration in the erythrocytes
were determined. The effect of homocysteine on adenosine uptake
was maximal after 6 minutes of uptake. To investigate the adenosine
concentration dependency of this homocysteine effect, an additional
series of experiments was conducted with 6 minutes of adenosine
uptake but with a variable adenosine concentration ranging from
0.125 mol/L to 2 mol/L (n4). Finally, we determined the
inhibiting effect of dipyridamole (0.2 mol/L, 5-minute incubation)
on the accelerating effect of homocysteine with 6 minutes of
adenosine uptake (n2).
Drugs and Solutions
Solutions of adenosine (Adenocor, Sanofi-Synthelabo) and dipyri-
damole (Persantin, Boehringer Ingelheim) were freshly prepared
with NaCl 0.9% as solvent. L-homocysteine was freshly prepared
immediately before each in vitro experiment from L-homocysteine
thiolactone as previously described.14
Analytical Procedures
Dialysate adenosine concentration was determined by high-perfor-
mance liquid chromatography (HPLC) with reversed-phase ion-
pairing separation and UV detection. Plasma homocysteine was
determined by reverse phase (RP)-HPLC as described previously.15
Plasma AdoHcy and AdoMet were determined by tandem mass
spectrometry, based on the work of Struys et al.16
Figure 1. Simplified representation of the biochemical reactions
relevant to our hypothesis. Under normal conditions, adenosine
is continuously produced by the hydrolysis of AdoHcy (left). In
hyperhomocysteinemia, adenosine production from AdoHcy
hydrolysis is hampered or the reaction is even reversed, and
AdoHcy will accumulate at the expense of free adenosine (right).
Dipyridamole inhibits cellular adenosine uptake by blockade of
the ENT. AMP indicates adenosine mono-phosphate; 5-NT,
5-nucleotidase; ADA, adenosine deaminase; AK, adenosine
kinase; Ino, inosine; Met, methionine; ENT, equilibrative nucleo-
side transporter.
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Statistics
Values are expressed as meanSE unless otherwise stated. P0.05
is considered statistically significant. Because plasma concentrations
of homocysteine, AdoHcy, AdoMet, and vitamins did not show a
Gaussian distribution (P0.1; Shapiro–Wilk test for normality), the
Mann–Whitney test was used to compare groups. Other baseline
parameters were normally distributed, and consequently a Student t
test was used.
To compare adenosine-induced vasodilation between the two
groups, a repeated measures ANOVA was used. Finally, for each
subject, the area under the curves (AUC) of change in FBF was
calculated for the adenosine-induced vasodilation with and without
dipyridamole. The ratio of the AUC (with dipyridamole) and the
AUC (without dipyridamole) was used to quantify the effect of
dipyridamole. Because these ratios were not normally distributed, a
Mann–Whitney test was used to compare groups.
In the in vitro experiments, the decrease of extracellular adenosine
in time was fitted according to one phase exponential decay
(GraphPad Prism version 4.00 for Windows, GraphPad Software),
and half times were compared with paired Student t test.
Results
Baseline Characteristics
Demographic data are shown in Table 1. Plasma concentra-
tions of total homocysteine, AdoHcy, and AdoMet were
higher in the patient group (P0.005). Treatment with
high-dose folic acid and pyridoxine resulted in higher plasma
concentrations of folate and vitamin B6 in the patient group
(P0.005). In one patient, we were not able to insert the
intravenous probe and intraarterial cannula, and consequently
only data on interstitial adenosine were available.
Microdialysis Experiments
Immediately after intramuscular insertion, dialysate adeno-
sine concentration is known to be high because of myocyte
damage and decreases to baseline level within one hour.9 To
estimate basal interstitial adenosine concentration, we aver-
aged the dialysate concentration of the two consecutive
dialysate samples taken 1.5 hours after insertion. In the
patient group, basal adenosine concentration was 9621
nmol/L (n7; 2 patients were excluded because of extremely
low concentration of creatine and phosphocreatine in the first
microdialysis sample, indicating misplacement of the probe),
whereas in the control group basal adenosine concentration
was 739 nmol/L (n8, P0.3).
The dialysate adenosine concentration from the intravas-
cular probe was at steady-state immediately after insertion.
Therefore, we averaged the values of all dialysate samples to
one value. In the patient group this baseline concentration
yielded 14233 nmol/L (n8), whereas in the control group
it yielded 13525 nmol/L (n8, P0.7). Adenosine recov-
ery of the intramuscular and intravascular probes was 484%
and 475% for patients and 474% and 392% for con-
trols, respectively (P0.9 and 0.2, respectively).
Plethysmography Experiments
Baseline FBF in the infused arm was 2.00.2 and 2.50.5
mL/min/dL for patients and controls, respectively (n8;
P0.4). During infusion of increasing adenosine dosages,
FBF in the patient group was 2.90.4, 4.30.5, 5.61.1, and
9.62.1 mL/min/dL, respectively (Figure 2). In the control
group, FBF was 2.80.6, 4.41.0, 9.01.7, and 17.03.1
mL/min/dL, respectively. This adenosine-induced vasodila-
tion was attenuated in the patient group (P0.05).
After 30-minute equilibration, baseline FBF was 2.70.3
and 3.10.7 mL/min/dL in the patient group and control
group, respectively (n8; P0.6). Infusion of dipyridamole
increased FBF to 4.30.5 mL/min/dL in patients and to
4.71.0 in controls (P0.7 between groups). Subsequent
infusion of adenosine on top dipyridamole increased FBF to
10.91.6, 16.32.6, and 27.22.9 mL/min/dL in patients
and to 8.81.4, 14.82.4, and 24.44.0 in controls, respec-
tively (P0.9). The ratio of the AUC for adenosine-induced
vasodilation with dipyridamole and without dipyridamole
was 0.400.08 in the patient group and 0.160.03 in the
control group (P0.05). Moreover, with both experimental
groups taken together, there was a negative correlation
between total plasma homocysteine concentration and the
TABLE 1. Demographic Characteristics of the Study Groups
Patients Controls
No. 9 8
Sex (male/female) 8/1 6/2
Age (years) 36.32.2 36.84.9
Body mass index (kg/m2) 25.40.9 24.41.5
Smoking (No.) 3 3
Systolic blood pressure (mm Hg)* 1264 1163
Diastolic blood pressure (mm Hg)* 724 673
Heart rate (bpm)† 644 572
Glucose (mmol/L) 4.90.1 5.20.3
Cholesterol (mmol/L) 4.90.3 4.60.3
Total homocysteine (mol/L) 93.124.7‡ 9.11.0
S-adenosylhomocysteine (nmol/L) 41.810.0‡ 7.70.8
S-adenosylmethionine (nmol/L) 389.897.1‡ 96.88.5
Vitamin B12 (pmol/L) 25818 28430
Vitamin B6 (nmol/L) 4315305‡ 755
Folate (nmol/L)§ 15539‡ 121
*Intra-arterially and †electrocardiographically measured during saline infu-
sion.
‡P0.005 compared to control group.
§Upper limit of detection 270 nmol/L.
Figure 2. Adenosine-induced vasodilation without dipyridamole
(squares) and during coinfusion with dipyridamole (triangles) in
patients (open symbols; meanSE, n8) and controls (filled
symbols; n8).
Riksen et al Adenosine in Hyperhomocysteinemia 111
AUC for adenosine-induced vasodilation (Spearman
r0.53, P0.035) and a positive correlation between
plasma homocysteine and the effect of dipyridamole ex-
pressed as the ratio of the AUC’s for adenosine-induced
vasodilation with and without concomitant infusion of dipyr-
idamole (Spearman r0.59, P0.015).
During the experiment, neither mean arterial pressure
(MAP) nor the FBF in the control arm differed between the
patient group and the control group (P0.1; ANOVA for
repeated measures). The effects of adenosine infusion on
heart rate and blood pressure are shown in Table 2. Concom-
itant infusion of adenosine with dipyridamole was associated
with an increase in heart rate in both groups (ANOVA for
repeated measures, P0.001). Also, infusion of adenosine
without dipyridamole was associated with an increase in heart
rate in the patient group (P0.05). Blood pressure was not
influenced by adenosine infusion. There were no differences
between both groups.
Finally, minimal forearm vascular resistance (MAP/FBF)
during postocclusive reactive hyperemia was 2.10.2 and
2.40.2 AU for patients and controls, respectively (P0.3).
Adenosine Uptake in Isolated Erythrocytes
Plasma homocysteine of the 6 subjects in this study averaged
9.10.9 mol/L. Adenosine uptake into the erythrocytes and
subsequent metabolism results in a decrease of extracellular
adenosine in time (Figure 3a). Adenosine uptake was accel-
erated by incubation with homocysteine (half time 6.40.3
versus 8.10.5 minutes, P0.001). Intracellularly, AdoHcy
increased in time in cells incubated with homocysteine, but
not in control samples (Figure 3b; P0.0001, ANOVA for
repeated measures). At 6 minutes, adenosine in the superna-
tant was lower in the homocysteine-incubated cells. This
absolute homocysteine-induced difference in adenosine con-
centration significantly increased when the initial adenosine
concentration was varied from 0.125 mol/L to 2.0 mol/L
(Figure 3c and 3d; P0.05, ANOVA for repeated measures).
Finally, dipyridamole significantly inhibited the accelerat-
ing effect of homocysteine on cellular adenosine uptake.
Homocysteine decreased the free extracellular adenosine
concentration after 6 minutes of adenosine uptake with
14.50.5% in the absence and with 2.90.5% in the pres-
ence of dipyridamole (Figure 4; P0.05, n2).
Discussion
In the present study, we show for the first time that adeno-
sine-induced forearm vasodilation is attenuated in patients
with hyperhomocysteinemia due to classical homocystinuria,
and that this attenuation is completely restored by coinfusion
of the adenosine uptake inhibitor dipyridamole.
The association between hyperhomocysteinemia and ath-
erosclerosis and thrombosis was first established in patients
with classical homocystinuria.17 Without treatment, 50% of
suchlike patients experience a vascular event before the age
of 30 years.18 Treatment is aimed at minimizing the biochem-
ical abnormalities and consists of pyridoxine (vitamin B6)
and folic acid and, if necessary, betaine anhydricum and
vitamin B12.19 This treatment regimen significantly improves
vascular outcome.20 Our patients continued to have elevated
plasma homocysteine levels despite treatment. Because of the
defective degradation of homocysteine to cystathionine, ho-
mocysteine can only be remethylated to methionine or con-
verted to AdoHcy. This altered metabolic profile is illustrated
by the increased plasma concentrations of AdoHcy and
TABLE 2. Systemic Effects of Adenosine Infusion
Heart Rate Mean Arterial Pressure
Patients Controls Patients Controls
Baseline 1 624 572 934 863
Ado 0.5 614 551 934 863
Ado 1.5 634 561 934 874
Ado 5.0 624 561 964 834
Ado 15.0 653* 572 964 873
Baseline 2 644 572 964 893
Dipy 665 572 974 893
Dipyado 0.15 694 602 974 883
Dipyado 0.5 704 632 994 904
Dipyado 1.5 765† 702† 995 894
*Significant increase in heart rate as compared to baseline 1 (P0.05) and
†baseline 2 (P0.001). No differences between groups.
Figure 3. Time-course of adenosine concentration in the super-
natant (a) and the intracellular AdoHcy concentration (b) after
addition of 1 mol/L of adenosine to erythrocytes. Also shown
is the adenosine concentration in the supernatant 6 minutes
after the addition of variable concentrations of adenosine (c;
n4) and the absolute homocysteine-induced difference in
adenosine concentration after 6 minutes of uptake (d; n4).
Open squares indicate incubation with homocysteine; filled
squares, control group.
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AdoMet in our patient group. Previous in vivo experiments
on vascular function in this patient group are scarce and
demonstrated impaired flow-mediated dilation and carotid
artery wall hypertrophy.21–23
In the present study, adenosine-induced forearm vasodila-
tion was reduced in patients with hyperhomocysteinemia.
Based on the observations that dipyridamole restores this
impaired vasodilation and that in erythrocytes homocysteine
accelerates cellular adenosine uptake, we conclude that this
impaired adenosine-induced vasodilation is caused by accel-
erated cellular adenosine uptake. Adenosine-induced vasodi-
lation is partly endothelium-dependent.24 We did not use
alternative endothelium-dependent vasodilators to test for
endothelial function in our patient group. However, as shown
by previous studies in patients with classical homocystinuria,
endothelial dysfunction could well also be present in our
patients. Could endothelial dysfunction or structural vascular
damage, both previously described in a comparable patient
group, challenge our conclusion? In our opinion this is not the
case. The observation that dipyridamole restored adenosine-
induced vasodilation suggests that accelerated adenosine
uptake through the equilibrative nucleoside transporter, rather
than endothelial dysfunction, accounts for the attenuated
vasodilation. It needs to be realized that dipyridamole is
proposed to have alternative mechanisms of actions besides
inhibition of nucleoside transport.25 Phosphodiesterase inhi-
bition could theoretically potentiate endothelium-dependent
cGMP-mediated dilation, thus improving this portion of
adenosine-induced vasodilation. However, in an identical
experimental model as in the present study, our group has
previously shown that dipyridamole-induced local vascular
effects are indeed solely caused by adenosine uptake inhibi-
tion. Dipyridamole potentiated the vasodilator response to
adenosine,10 and dipyridamole-induced vasodilation (100 g/
min/dL) was inhibited by the adenosine receptor antagonist
theophylline.26 Moreover, we showed in isolated erythrocytes
that homocysteine indeed accelerates cellular adenosine up-
take, which is counteracted by dipyridamole. Although the
effects of homocysteine in this model are rather modest, these
in vitro observations provide additional evidence that accel-
erated cellular adenosine uptake might account for the ob-
served impaired adenosine-induced vasodilation.
Minimal forearm vascular resistance was similar in both
groups. This parameter accurately reflects structural arteriolar
status,27 indicating that in our patient group, at least in the
forearm vascular bed, no structural vascular changes were
present. It should be mentioned that reactive hyperemia is
shown to be partially adenosine-dependent.28 This portion of
the hyperemia in our study would theoretically be diminished
in the patients with hyperhomocysteinemia. However, be-
cause of the maximal stimulus for vasodilation after 13
minutes of ischemia, other mediators probably compensate
for this decrease in adenosine-induced vasodilation.27
In previous experiments, it was shown in guinea pig
hearts29,30 and rat brain31 that perfusion with homocysteine
(thiolactone) decreased organ release of adenosine. The
results from our in vitro experiments showed that also in
human erythrocytes, homocysteine accelerates cellular uptake
of adenosine. Moreover, we demonstrated that this is indeed
associated with increased intracellular formation of AdoHcy.
Finally, this effect of homocysteine is more pronounced at
higher concentration of adenosine (Figures 2 and 3). This
observation could well explain why baseline endogenous
adenosine, as estimated by microdialysis, was not reduced in
our patient group. This is in strong contrast to the study by
Chen et al, which demonstrated an 50% reduction in
endogenous baseline adenosine concentration induced by
mild elevation of plasma homocysteine from 6.70.4 to
14.70.5 mol/L.2 This discrepancy could be caused by the
differences between man and rat concerning protein-binding
of homocysteine,6 AdoHcy hydrolase activity,3 and charac-
teristics of the equilibrative nucleoside transporter.32 Also,
the experimental methionine-induced hyperhomocysteinemia
in the rat model differs from the hyperhomocysteinemia in
our patient group, possibly affecting tissue and cellular
distribution of homocysteine. But most importantly, the
results from our in vitro studies suggest that the effect of
AdoHcy synthesis on the rate of cellular adenosine uptake is
limited to situations of high extracellular adenosine concen-
trations, as for example in ischemia, when myocardial inter-
stitial adenosine concentration can increase up to 40-fold in
pigs.7 A recent microdialysis study on the pig heart showed
that local application of homocysteine reduced dialysate
adenosine concentration during hypoxia, but not during
normoxia.7 Likewise, Kloor et al concluded from a rat study
that homocysteine is the rate-limiting factor for AdoHcy
synthesis in hypoxic conditions when tissue levels of adeno-
sine are elevated, whereas in normoxia the availability of free
adenosine is rate-limiting.6 This suggests that also in vivo, the
effect of homocysteine on adenosine concentration is more
pronounced and therefore more easily detected in situations
of high concentrations of adenosine than under normoxic
baseline conditions. Unfortunately, for practical reasons we
were not able to collect microdialysis samples during infusion
of adenosine or during ischemia.
We have shown that the vasodilating effect of adenosine,
which was reduced in hyperhomocysteinemia, was com-
Figure 4. Extracellular concentration of adenosine after 0 and 6
minutes of adenosine uptake by isolated human erythrocytes in
the absence (open bars) and presence (filled bars) of homocys-
teine. Dipyridamole significantly reduces the accelerating effect
of homocysteine on adenosine uptake (P0.05, n2).
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pletely restored by the nucleoside uptake inhibitor dipyridam-
ole. Extrapolating this finding, dipyridamole would be bene-
ficial in patients with hyperhomocysteinemia by preserving
the protective cardiovascular effects of adenosine in hypoxia
or ischemia. To our best knowledge, dipyridamole has never
been tested systematically in such patients in clinical trials.
Several limitations of the present study need to be dis-
cussed. First, we used a group of patients with classical
homocystinuria, using high doses of vitamins, including
vitamin B6 and folic acid. It remains to be established
whether changes in adenosine metabolism are also important
in patients with mild hyperhomocysteinemia. Considering the
vitamin therapy in our patient group, we are not aware of any
actions of these vitamins on nucleoside transport. Secondly,
considering the large interindividual variation, microdialysis
may lack sufficient sensitivity to exclude subtle differences in
baseline adenosine concentration between the two study
groups. Moreover, the values obtained with microdialysis
might not reflect the adenosine concentrations in specific
microenvironments, such as near the endothelial lining.
In conclusion, in patients with severe hyperhomocysteine-
mia, adenosine-induced effects are impaired, which could
contribute to the cardiovascular complications of this disease.
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